Grifols' Biotest receives FDA approval for innovative Yimmugo® immunoglobulin to treat primary immunodeficiencies

U.S. approval of Yimmugo paves the way for other Biotest proteins in late-stage development, including fibrinogen and trimodulin The first U.S.-approved medicine in Biotest's portfolio, Yimmugo is produced using a state-of-the-art process at Biotest's new FDA-certified "Next Level" production facility in Dreieich, Germany, which is already approved for production and marketing in Europe. Yimmugo, already approved for production and marketing in Europe, is the first U.S.-approved medicine in Biotest's portfo ...